Podcast: ASX Briefs – Sam Watson Interview
A 149% revenue surge, first‑to‑market GMP MDMA in Australia, and a plan to scale faster than demand—Sam Watson, CEO of Bioxyne, joins us to unpack how a focused manufacturer turns emerging therapeutics into real‑world access. We dig into the mechanics behind record growth, the patient need driving MDMA and psilocybin uptake, and why replicable GMP capacity across Australia, the UK, and Europe is Bioxyne’s not‑so‑secret weapon.
Sam explains how medicinal cannabis remains the commercial engine while psychedelic therapeutics validate a long‑term bet on treatment‑resistant depression and PTSD. With authorised prescriber pathways opening and imports giving way to local GMP supply, clinics gain reliable access and patients get consistent, pharmacy‑grade dosing. We talk through the numbers—upgraded adjusted EBITDA guidance to 16–19 million—and the process upgrades that power it: automation, digitised quality systems, and operating leverage as volumes climb.
We also map the international play. Germany leads as a prescriber‑led, pharmacy‑dispensed market where cannabis flower dominates and Bioxyne targets five to ten tons over the next year through strong local partnerships. The UK mirrors Australia’s earlier stage, making it ripe for a copy‑and‑paste facility to relieve supply bottlenecks. Finally, Sam outlines how rapid clean room buildouts, short payback cycles, and white‑label reliability for 300+ brands create a durable moat: faster turnaround, fewer stockouts, and scalable quality at GMP standards.
Listen to the ASX Briefs podcast here: https://open.spotify.com/episode/1sSfcx8XvcKW16VpPOYV3c?si=pdizuRY-TQi8ftu0T9RmgA&nd=1&dlsi=c51597bc07e4492a